Health Care • Medical/Dental Instruments
$1.74 ▲ +0.00
(0.00%)
MKT CAP: $13.2M • VOL: 39.0K
52W L $1 52W H $19
ROARABLE / RQD
D- • 36/100
PIOTROSKI
2 / 9
CNSY // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $5.2M | $5.8M | $4.9M |
| YoY Revenue Growth % | -10.5% | +18.5% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$15.3M | -$14.7M | -$13.3M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$22.4M | -$13.0M | -$13.3M |
| EBITDA (Normalized) | -$15.2M | -$14.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$20.8M | -$10.6M | -$12.9M |
| Capital Expenditures (CapEx) | $67.0K | $146.0K | — |
| Free Cash Flow (FCF) | -$20.8M | -$10.7M | -$12.9M |
| FCF Margin % | -80.0% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $4.3M | $76.0K | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $4.0M | -$8.9M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR CNSY.